Last reviewed · How we verify

Mannitol (Aridol)

University of Saskatchewan · FDA-approved active Small molecule

Mannitol is an osmotic agent that draws fluid into the airways to increase airway hydration and mucus clearance, used diagnostically to assess airway hyperresponsiveness.

Mannitol is an osmotic agent that draws fluid into the airways to increase airway hydration and mucus clearance, used diagnostically to assess airway hyperresponsiveness. Used for Diagnostic assessment of airway hyperresponsiveness in suspected asthma, Evaluation of exercise-induced bronchoconstriction.

At a glance

Generic nameMannitol (Aridol)
SponsorUniversity of Saskatchewan
Drug classOsmotic agent / Diagnostic bronchial challenge agent
ModalitySmall molecule
Therapeutic areaRespiratory / Diagnostics
PhaseFDA-approved

Mechanism of action

Mannitol powder is inhaled and acts as an osmotic agent, drawing water into the airway lumen and increasing airway surface liquid volume. This hydration of airways stimulates mast cell degranulation and airway smooth muscle contraction in individuals with airway hyperresponsiveness, making it useful as a bronchial challenge test to diagnose asthma and assess airway function.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: